

INFORMATION DISCLOSURE CITATION

ATTORNEY'S DKT No. 012712-905

APPLICATION No. Not Assigned

APPLICANT

Nabil HANNA et al. FILING DATE

	PTO-144	49	FILING DATE July 10, 2000	GROUP Not Assigned							
		<u> </u>	. PATEN	T DOCUMENTS			<u> </u>				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME		CLASS	SUBCLASS	FILIN	G DAT			
	4,816,567	3/28/89	Cabilly	et al.	530	387	0	<u> </u>			
	4,973,745	12/18/90	Schoe	naker et al.	530	387	4.7				
	4,975,369	12/04/90	Beaver	s et al.	435	69	25.0				
	4,816,397	3/28/89	Boss e	t al.	435	68	9/60				
							Č.				
, 		FOREIC	ON PATE	NT DOCUMENTS			1				
EXAMINER'S INITIALS	PATENT NO. DATE			COUNTRY	AND THE STREET, STREET		Tran	slation			
	9008198	7/26/90	PCT	COUNTRY	CLASS	SUBCLASS	Yes	No			
	EP 0 523 949 A1	01/20/93	EURO	PE	 		ļ	-			
	EP 0 451 216 B1	10/16/91	EUROF				ļ	<u> </u>			
	EP 0 682 040 A1	11/15/95	EUROF	E	 						
	OTHER DOCUM	ENTS (Includ	ding Aut	or, Title, Date, Per	rtinent Page	s Étc)					
	Jones, P.T. et al., N	Nature, 321:	522, (19	86)							
	Camerini, D. and Se	ed, B., Cell,	60:747	(1990)	<u>-</u> -						
	McClure, M.O. et a										
	Truneh, A. et al., Cell. Immun., 131:98, (1990)										
	Nishimura, Y. et al., Cancer Research, 47:999 (1987)										
	Ward, E.S. et al., Nature, 341:544 (1989)										
	Camerini, D. and Se 587, (1989)				rnational Co	onference on	AIDS	, pg.			
	Persson et al., Proc.	A 88:2432 1991									
	Persson et al., Proc. Natl. Acad. Sci. USA, 88:2432, 1991 Meek et al., J. Immun., 146:2434, 1991										
	Allison et al., J. Immunological Methods, 95:157, 1986										
	· · ·										
	Ehrlich et al., Hybridoma, Vol. 7, No. 4, pp. 385-395, 1988 Ehrlich et al., Clin. Chem., 34:1681, 1988										
	Van Meel et al., J. Immunological Methods, 80:267, 1985										
	BS Heteromycloma I	ine abstract	ii iAIGTUO	15, 00.207, 1985							
				1000 1.1							
XAMINER	Ehrlich et al., Hum. Antibod. Hybridomas, 1990, vol. 1, no. 1. DATE CONSIDERED										

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 OF 3

			_							
INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT No. 012712-905			APPLICATION NO. Not Assigned			
				APPLICANT Nabil HANNA et al.						
				FILING DATE July 10, 2000			GROUP Not Assigned			
	<u> </u>	U.S. PATENT	ØD	OCUMEN	тs					
EXAMINER'S							FILING I			
INITIALS	PATENT NO. DATE			NAME		CLASS	SUBCLASS			
							ļ			
	·									
						-	1			
						-				
			Circ A				<u> </u>			
		FOREIGN PATE	ΠT	DOCUM	ENIS.		<u> </u>	Transl	lation	
EXAMINER'S	PATENT NO. DATE			OUNTRY		CLASS	SUBCLASS	Yes	No	
INITIALS	PATENT NO.				-			,	1	
				.		 	 		┢╴	
					. 			<u> </u>	├—	
							1		<u> </u>	
	 		_							
	<u> </u>		***			March 1		19. 7		
		UMENTS (Including Au					ges, Etc./	THE STATE OF THE S		
		Hybridoma, Vol. 6, No.	2,	pp. 151-	160, 198	<u> </u>			_	
	Herpes Transformation, abstract									
	Amoroso et al., J. Immun., 145:3155, 1990									
	Huse et al., Science, 246:1275, 1989									
	Letvin, et al., Effect of Recombinant Soluble CD4 in Rhesus Monkeys Infected With Simian Immunodeficiency Virus of Macaques, Abstract from the V Int. Conf. on AIDS, 1989, p. 535.									
	Rosenberg, M. et al., <u>Biotherapy</u> , "Soluble recombinant CD4 - A potential therapeutic agent for HIV infector", 2:107, (1990)									
-	(1988)	et al., <u>Nature</u> , "Reshar			_					
	to the treatme	ent of cancer", 13:165,	inars in Oncology, "Monoclonal antibodies potential applications , 13:165, (1986).							
	(1991).	et al., Proceedings of						6-462	o, ——	
		al. JOURNAL OF IMMU			L METHO	DS (198	6) 123.			
	Morrison Science, Vol. 229, 1202 (1985)									
	Immunology Today 10:253 (1989)									
	Queen et al., PNAS 8610029 (1989)									
		Waldmann Science, Vol. 252, 1657, (1991)								
	Hied et al., G	enes and cancer (1990)) p							
EXAMINER	l .			DATE C	ONSIDER	ט=				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT N 012712-905	APPLICATION NO. Not Assigned			
				APPLICANT Nabil HANNA et al.				
						GROUP Not Assigned		
		U:	S. PATENT D	OCUMENTS	*			
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING	DATE
ж						<u> </u>		
		FOR	EIGN PATENT	DOCUMENTS		* .	T	
EXAMINER'S INITIALS	PATENT NO. DATE CO			DUNTRY	CLASS	SUBCLASS	Trans Yes	No No
				<u></u>	,			
		6 Agriconord	and the same of th	r, Title, Date, Per				Transfer of the second
	VOPR VIRUSOI lymphocyte sul cultures", page	opopulations	0, No. 5, issue transformed	ed October 1985, by baboon herpes	Markova virus in v	et al., "Monivivo and in tis	key B ssue	
	Harris et al., T.		ol. 11, page 4	2 (1993)				
	Truneh et al., "	Humoral Retivity Restric	sponse of Cyr ted to Xeno-H	nomolgus Macaqu luman Determina	es to Hur nts" CELL	nan Soluble (ULAR IMMUI	D4: NOLOG	iΥ,
	Van Meurs et a	al. "Production	on of Primate	Monoclonal Antib I. 95, pp. 123-12		OURNAL OF		
	Schroeder et al. "Early Restriction of the Human Antibody Repertoire" SCIENCE, Nove 6, 1987, Vol. 238, Pages 791-793.							
	Immunoglobuli Deletion Mecha 1513-1522.	n Lambda Li anism" EURO	ght Chain Loc DPEAN JOURN	da-C Lambda Gen us are Separated NAL OF IMMUNO	by 14 KB LOGY, Ju	and Rearran ne 1991, Vol	ge by a . 21, F	ages
`	VL Domains of RH-Blood Grou Pages 135-140	Two Huma p System" 1).	n Monoclonal THE BIOCHEM	ces and Three-Dir Antibodies Specif ICAL JOURNAL,	fic for the May 15,	D Antigen of 1990, Vol. 26	f the H 88, No.	umar 1,
	Glycoprotein o Virus and Babo	f Human Imi oons Immuni	munodeficiend zed with a Ca	d to the Variable by Virus Type 1 in ndidate Recombir 3, No. 5, Pages	Chimpan nant Vacc	izees Infected ine" THE JOI	i with	the
EXAMINER				DATE CONSIDER				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.